Tarek Meniawy

Tarek Meniawy

Auto-generated profile, based on publicly available information

Tarek Meniawy

Saint John of God Subiaco Hospital, Subiaco, WA, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
Elin GrayElin Gray
Elin Gray
Helen RizosHelen Rizos
Helen Rizos
ARAnna Loreta Reid
Anna Loreta Reid
SBSuzanah C. Boyd
Suzanah C. Boyd
MPMichelle R. Pereira
Michelle R. Pereira
MZMelanie Ziman
Melanie Ziman
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

16 October 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
John M. KirkwoodJohn M. Kirkwood
John M. Kirkwood
MVMichele Del Vecchio
Michele Del Vecchio
JWJeffrey Weber
Jeffrey Weber
CHChristoph Hoeller
Christoph Hoeller
JGJean-Jacques Grob
Jean-Jacques Grob
GLGeorgina Venetia Long
Georgina Venetia Long
Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The primary endpoint was investigator-assessed recurrence-free survival (RFS). Secondary endpoints included distant metastasis-free survival (DMFS) and safety. At 7.8 months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR) = 0.42; 95% confidence interval (CI): 0.30–0.59; P < 0.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR = 0.47; 95% CI: 0.30–0.72). Treatment-related grade 3/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients. One treatment-related death (0.2%) occurred with nivolumab. Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB/C melanoma. ClinicalTrials.gov identifier: NCT04099251.

1 March 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
DODavid M. O'Malley
David M. O'Malley
MNMaryna Neffa
Maryna Neffa
Bradley MonkBradley Monk
Bradley Monk
TMTamar Melkadze
Tamar Melkadze
MHMarilyn Huang
Marilyn Huang
IŁIwona Ługowska
Iwona Ługowska
PURPOSE: Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882 ) evaluated the combination of balstilimab plus zalifrelimab in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy. PATIENTS AND METHODS: Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, RECIST version 1.1, assessed by independent central review). Secondary end points included duration of response, safety and tolerability, and survival. RESULTS: In total, 155 women (median age, 50 years [range, 24-76 years]) were enrolled and treated with balstilimab plus zalifrelimab; 125 patients had measurable disease at baseline and one prior line of platinum-based therapy in the advanced setting, and these patients constituted the efficacy-evaluable population. The median follow-up was 21 months. The confirmed ORR was 25.6% (95% CI, 18.8 to 33.9), including 10 complete responders and 22 partial responders, with median duration of response not reached (86.5%, 75.5%, and 64.2% at 6, 9, and 12 months, respectively). The ORRs were 32.8% and 9.1% in patients with programmed death ligand-1–positive and programmed death ligand-1–negative tumors, respectively. For patients with squamous cell carcinoma, the ORR was 32.6%. The overall disease control rate was 52% (95% CI, 43.3 to 60.6). Hypothyroidism (14.2%) and hyperthyroidism (7.1%) were the most common immune-mediated adverse events. CONCLUSION: Promising and durable clinical activity, with favorable tolerability, was seen in this largest trial to date evaluating dual programmed death-1/cytotoxic T-lymphocyte–associated antigen-4 blockade in patients with recurrent and/or metastatic cervical cancer. Further investigation of the balstilimab and zalifrelimab combination in this setting is continuing.

1 January 2020 in Cancer Letters
Verified
Journal Article
Open access
DADu-Bois Asante
Du-Bois Asante
LCLeslie Calapre
Leslie Calapre
MZMelanie Ziman
Melanie Ziman
TMTarek M. Meniawy
Tarek M. Meniawy
Elin GrayElin Gray
Elin Gray
Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.

1 April 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
FBFraser J.H. Brims
Fraser J.H. Brims
TMTarek M. Meniawy
Tarek M. Meniawy
IDIan Duffus
Ian Duffus
DFDuneesha de Fonseka
Duneesha de Fonseka
ASAmanda Segal
Amanda Segal
ANAnna K. Nowak
Anna K. Nowak

18 July 2014 in Thorax
Verified
Journal Article
Open access
PDF file
JCJenette Creaney
Jenette Creaney
IDIan M Dick
Ian M Dick
TMTarek M Meniawy
Tarek M Meniawy
SLSu Lyn Leong
Su Lyn Leong
JLJustine S Leon
Justine S Leon
BRBruce W S Robinson
Bruce W S Robinson
Background Pleural malignant mesothelioma (MM) is a deadly tumour predominantly associated with asbestos exposure. A reliable diagnostic and prognostic marker for MM will significantly enhance clinical care and is an area of intense research. Soluble mesothelin is the most studied and an FDA-approved biomarker for MM. A recent report showed promising results using fibulin-3 as a new diagnostic marker. The aim of this study was to compare the utility of fibulin-3 versus mesothelin, singly or in combination. Methods Fibulin-3 and soluble mesothelin were determined by ELISA in the plasma and pleural fluid of 153 patients presenting with a pleural effusion including 82 with MM, 36 with non-MM malignant effusions and 35 with benign effusions. Biomarker concentrations were determined in the plasma of an additional 49 cases with benign asbestos-related disease. Results Mesothelin provides better diagnostic accuracy than fibulin-3 for MM whether measured in plasma or pleural effusion: area under the curve (AUC) for plasma was 0.822 (95% CI 0.76 to 0.87) compared with 0.671 (0.61 to 0.73), respectively, and for pleural fluid AUC was 0.815 (0.74 to 0.87) compared with 0.588 (0.51 to 0.67), respectively. Effusion fibulin-3 was an independent significant prognostic factor for survival in MM patients; HR 2.08 (1.14 to 3.82), p=0.017. MM patients with effusion fibulin-3 levels below the median survived significantly longer than those with levels above the median (14.1 vs 7.9 months, p=0.012). Mesothelin and neutrophil to lymphocyte ratio were not significant prognostic markers. Conclusions Soluble mesothelin is a superior diagnostic biomarker for MM compared with fibulin-3, whereas fibulin-3 provides superior prognostic information compared with mesothelin.